Holen Sie sich die Stockscreener-App
7.23
8.23%
0.55
Handel nachbörslich:
7.10
-0.13
-1.80%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
JPMorgan Chase & Co. Raises Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00 - MarketBeat
SLDB: JP Morgan Raises Price Target to $12 with Overweight Ratin - GuruFocus
HC Wainwright Expects Higher Earnings for Solid Biosciences - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20 - Moomoo
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Guggenheim initiates coverage of Solid Biosciences (SLDB) with buy recommendation - MSN
Evolving Tax Rules and New Excise Levies Threaten Solid Biosciences’ Profitability and Cash Flows - TipRanks
RA CAPITAL MANAGEMENT, L.P. Reduces Stake in Solid Biosciences Inc - GuruFocus
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Guggenheim Initiates Coverage on Solid Biosciences (SLDB) with B - GuruFocus
Will Solid Biosciences Inc stock recover after earnings2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Shares Gap UpWhat's Next? - MarketBeat
Solid Bio stock wins new Buy at Guggenheim (SLDB:NASDAQ) - Seeking Alpha
SLDB: Guggenheim Initiates Coverage with a 'Buy' Rating at $26 | - GuruFocus
Guggenheim Initiates Coverage on Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from Chardan Capital - MarketBeat
Solid Biosciences (SLDB) Receives Maintained 'Buy' Rating from C - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Solid Biosciences (SLDB) Receives Buy Rating and Positive Outlook - GuruFocus
Guggenheim Initiates Solid Biosciences at Buy With $26 Price Target - marketscreener.com
SLDB: Needham Reiterates 'Buy' Rating with Price Target of $19.0 - GuruFocus
Solid Biosciences Inc. 2025 Annual Report: Advancing Gene Therapy for Neuromuscular and Cardiac Diseases - Minichart
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Sentiment Recap: Whats the beta of Solid Biosciences Inc stock2026 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Solid Biosciences (SLDB) Strengthens Financial Position with Inc - GuruFocus
Solid Biosciences (NASDAQ: SLDB) resale registration for 42.8M shares - Stock Titan
[S-3] Solid Biosciences Inc. Shelf Registration Statement | SLDB SEC FilingForm S-3 - Stock Titan
Solid Biosciences Reports Positive Interim Data for SGT-003 and Advances Clinical Programs in Duchenne Muscular Dystrophy, Friedreich’s Ataxia, and CPVT - Quiver Quantitative
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewswire
Gene therapy pipeline at Solid Biosciences (NASDAQ: SLDB) targets Duchenne and cardiac disease - Stock Titan
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Solid Biosciences Inc. spotlights leadership role in Friedreich ataxia research collaboration - Traders Union
According to the latest disclosure documents from the U.S. Securities and Exchange Commission, biotechnology company Solid Biosciences has submitted a resale prospectus, and a certain shareholder of the company plans to resell up to 1.3 million shares o - Bitget
Geopolitics Watch: What analysts say about Solid Biosciences Inc stockWeekly Trade Review & Reliable Entry Point Alerts - baoquankhu1.vn
PERCEPTIVE ADVISORS LLC Increases Stake in Solid Biosciences Inc - GuruFocus
RA Capital boosts Solid Biosciences (SLDB) ownership to 9.9% with March buys - Stock Titan
H.C. Wainwright Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences reports interim data from Duchenne gene therapy trial - Investing.com Nigeria
Citizens reiterates Solid Biosciences stock rating on trial data By Investing.com - Investing.com Canada
Boxer Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDB - MarketBeat
Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB - MarketBeat
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR) - The Globe and Mail
Friedreich Ataxia research spotlight as Solid Biosciences advances SGT-212 clinical trials - Traders Union
Options Flow: What analysts say about Solid Biosciences Inc stockExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Solid Biosciences reports interim data from Duchenne gene therapy trial By Investing.com - Investing.com Australia
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha
Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Yahoo Finance
Truist reiterates Buy on Solid Biosciences stock after trial data By Investing.com - Investing.com Australia
SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Truist reiterates Buy on Solid Biosciences stock after trial data - Investing.com
Chardan Capital Reaffirms "Buy" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data - TipRanks
Barclays Maintains Solid Biosciences (SLDB) Overweight Recommendation - MSN
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Solid Biosciences (NASDAQ: SLDB) reports promising SGT-003 Duchenne data - Stock Titan
Perceptive invests $49.9M via warrants in Solid Biosciences (SLDB) - Stock Titan
Perceptive Life Sciences fund acquires 8.9M SLDB pre-funded warrants in Solid Biosciences (SLDB) - Stock Titan
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
Solid Biosciences (SLDB) Shares Drop After New Trial Data Releas - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3%Time to Sell? - MarketBeat
Solid Biosciences shares fall after gene therapy trial data - Investing.com
Solid Bio falls amid new trial data for Duchenne drug - Seeking Alpha
Solid Biosciences shares fall after gene therapy trial data By Investing.com - Investing.com India
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):